ARK Genomic Revolution ETF (ARKG)
| Assets | $1.23B |
| Expense Ratio | 0.75% |
| PE Ratio | n/a |
| Shares Out | 41.20M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| Volume | 2,511,965 |
| Open | 31.73 |
| Previous Close | 31.90 |
| Day's Range | 30.79 - 31.76 |
| 52-Week Low | 17.51 |
| 52-Week High | 34.07 |
| Beta | 1.67 |
| Holdings | 35 |
| Inception Date | Oct 31, 2014 |
About ARKG
Fund Home PageThe ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is issued by ARK.
Top 10 Holdings
57.46% of assets| Name | Symbol | Weight |
|---|---|---|
| Tempus AI, Inc. | TEM | 9.43% |
| CRISPR Therapeutics AG | CRSP | 8.63% |
| Personalis, Inc. | PSNL | 6.21% |
| Guardant Health, Inc. | GH | 5.68% |
| Twist Bioscience Corporation | TWST | 5.46% |
| Beam Therapeutics Inc. | BEAM | 4.86% |
| Natera, Inc. | NTRA | 4.51% |
| 10x Genomics, Inc. | TXG | 4.47% |
| Recursion Pharmaceuticals, Inc. | RXRX | 4.30% |
| Veracyte, Inc. | VCYT | 3.91% |
Performance
ARKG had a total return of 18.45% in the past year, including dividends. Since the fund's inception, the average annual return has been 4.64%.
News
Investing In Health Stocks - How Policy Clarity Is Opening Doors
The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discoun...
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
ARKG: I'm Holding Off Buying For These 3 Reasons
I maintain a hold rating on ARK Genomic Revolution ETF due to unprofitable top holdings, high operating costs, and limited approved treatments despite revenue growth. ARKG's high expense ratio and lac...
Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade
Ark Invest CEO Cathie Wood is known for her stock picks over the last decade, handpicking many of the growth stocks that find their way into the company's ETFs.
ARKG: April's Wash-Out Low Is Encouraging, Healthcare Still Soft
I reiterate a soft buy rating on ARKG, despite recent sector weakness and mixed technicals, due to its rebound and improving valuation. ARKG stands out for its concentrated portfolio, high risk/reward...
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...
Cathie Wood on DeepSeek, Nvidia, Stock Picks, China, AI
Chinese AI startup DeepSeek has released a new open-source AI model called R1 that can mimic human reasoning, rivalling or outperforming leading US developers on industry benchmarks. The release of R1...
ARKG: Eyeing Favorable Macro 2025 Turns, Encouraging Momentum Trends
I maintain a buy rating on ARK Genomic Revolution ETF (ARKG) due to improving momentum, potential lower interest rates, and a favorable M&A environment in 2025. Despite a 20% decline in 2024, ARKG's t...
Here Are the 6 Largest Stock Holdings in All of Cathie Wood's ETFs Right Now
Asset management company Ark Invest offers nine different investment funds, eight of which are available as exchange-traded funds, or ETFs. They all have a different tech-related focus, such as roboti...
Interest Rate Regimes And ARKG: Underperformance Explained
ARKG's top holdings were replaced due to poor performance, highlighting the fund's vulnerability to interest rate changes and high concentration in cash-burning companies. ARKG underperformed signific...
Almost Every Ark Fund Is Now Underperforming The Overall Market. Here's Why.
Ark Funds pull exclusively from different slivers of the technology sector that also tend to be the most volatile. Economic conditions can make a bigger performance difference over the long term than ...
ARKG: A Genomics Play But Active Isn't Adding Value
Genomics is rapidly advancing, shaping our understanding of health, disease, and life itself. Consider investing in the ARK Genomic Revolution ETF for exposure to leading genomics companies. ARKG's ac...
BMO Transfers 3 BMO Mutual Fund ETF Series, Managed by ARK Investment Management, to Cboe Canada
TORONTO--(BUSINESS WIRE)---- $ARKG #Cboe--Cboe Canada is pleased to announce BMO has transferred three BMO mutual fund ETF series, trading under the symbols ARKK, ARKW, and ARKG to Cboe Canada.
Here's How Cathie Wood (Almost) Completely Missed the Boat on Artificial Intelligence (AI) -- and the Simplest Way You Can Avoid Making the Same Mistake
Despite touting growth themes in a growth-fueled market, ARK Invest's exchange-traded funds are noticeably trailing major benchmarks. Betting big on a few companies can lead to massively outsize gains...
Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April
Hello! This week's ETF Wrap digs into the slump in ETF flows in April and investor positioning around commodities as inflation worries persist.
3 Cathie Wood ETFs Just Hit 4-Month Lows. Are They Worth Buying Now?
There are better ways to approach innovation than the Ark Innovation ETF. The ARK Space Exploration & Innovation ETF is a balanced bet.
ARKG: Massive Potential, But Not Worth The Risk Yet For These 3 Reasons
ARK Genomic Revolution ETF warrants a hold rating due to multiple roadblocks preventing solid returns, including underdeveloped technology, legal hurdles, and unresolved ethical dilemmas. ARKG has a r...
Cathie Wood Speaks, ARK Investors Should Listen
Cathie Wood criticizes the US Federal Reserve for its monetary policy mistakes and argues that deflation, not inflation, should be the concern. Wood presents charts showing that technologically driven...
China-focused ETFs struggle amid fears of another regulatory ‘crackdown'
Hi! This week's ETF Wrap funds looks at China-focused funds that are struggling in 2024, with Clocktower's chief strategist Marko Papic providing his take on concerns tied to the country.
1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years
Cathie Wood is known for investing in cutting-edge innovators. Her ARK Genomic Revolution ETF owns several gene-editing companies, but Prime Medicine might be the best of the bunch.
Analyzing ARKG's Trading Activity In Q3
ARK Genomic Revolution ETF focuses on genomic innovation in sectors such as healthcare, information technology, and energy. The fund's buying and selling activity gives us clues about the degrees of c...
How to Find the Best Biotech ETFs
The best biotech ETFs allow investors a diversified way to play the volatile biotechnology industry. Here's how to find them.
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?
In September, Cathie Wood and Ark Invest bought shares of Beam Therapeutics more than a dozen times. Beam Therapeutics is a clinical-stage drugmaker with a unique approach to developing new gene thera...
ARKG ETF: An Enticing Play, But Risks Galore
The ARK Genomic Revolution ETF is a $2bn actively managed ETF that focuses on companies leveraging genomics in their products and services. Genomic-based applications have the potential to revolutioni...
3 Top Growth ETFs to Buy Right Now
Growth stocks have rebounded this year after a broad sell-off in 2022. Growth-oriented exchange-traded funds, or ETFs, are an easy and straightforward way to take advantage of this emerging trend.
Cathie Wood Is Buying Up Shares of This Beaten-Down Biotech. Should You?
Superstar investor Cathie Wood bought shares of Moderna over a period of two days this week. The biotech company may become a respiratory vaccine giant -- with coronavirus, RSV, and flu vaccines -- in...
Cathie Wood Says ARK Funds Are Seeing Flows Coming Back
ARK Invest CEO and CIO Cathie Wood comments on ARK's fund flows during an interview with Romaine Bostick and Katie Greifeld on "Bloomberg Markets: The Close."
Here's the Secret Behind Cathie Wood's Latest Moneymaking Strategy
Cathie Wood is swinging for the fences with several gene-editing stocks. She's also making shrewd short-term trades with these stocks.
ARKG: A Probable Window Of Opportunity, Depending On Banks And The Fed
Cathie Wood's ARKG provides investors with an opportunity to take advantage of the billion-dollar genomics market. However, it has performed poorly compared to XLV's higher-quality holdings in a perio...